From trial phases to personalized care, here’s how healthcare providers can navigate cancer clinical trials and guide ...

Rejuvenate Biomed, an AI-enabled, clinical-stage biotech company developing safe, synergistic combination therapeutics that alter the course of age-related diseases, announced today that the first ...

SYL1801 is an investigational siRNA therapy administered via eye drops, rather than intravitreal injection, to treat nAMD.

Rejuvenate Biomed has dosed the first subject in the randomised Phase II trial to assess its lead compound, RJx-01.

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout ...

Global phase III trials demonstrate that nerandomilast slowed lung function decline in IPF and PPF, with similar discontinuation rates to placebo -- Nerandomilast, an investigational ...

Investors now have three ASX-listed stem cell therapy companies to choose from – and we can thank Mesoblast for inspiring the third.

Sponsored communities reduce timelines and increase relevance. Digital engagement allows for rapid study launches and ...

Patients given Neuronata-R who progressed more slowly saw significant gains in CAFS, slower declines in ALSFRS-R scores, and ...

Late-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect ...

No longer will our medicines be gated through animals, but rather through entirely human systems — leading to breakthrough ...

Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phas ...